Galectin-3 and oral submucous fibrosis
Not Applicable
- Conditions
- Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynxHealth Condition 2: K135- Oral submucous fibrosis
- Registration Number
- CTRI/2020/12/029928
- Lead Sponsor
- Dr Hetvi Sheth
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Clinically diagnosed cases of OSMF with or without malignant transformation.
Exclusion Criteria
1. Patient who has undergone any kind of invasive treatment for OSMF before.
2. Patient with any systemic and infectious disease.
3. The patient who is not willing to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Role of Galectin-3 in pathogenesis of Oral submucous fibrosisTimepoint: 8 weeks
- Secondary Outcome Measures
Name Time Method Role of Galectin-3 in pathogenesis of Oral submucous fibrosisTimepoint: 8 weeks